GLP-1 clinical trials in Maryland: 23 recruiting now

23 GLP-1 clinical trials are recruiting at 28 sites in 10 cities across Maryland. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Maryland

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   3 sites in Maryland

   • Johns Hopkins School of Medicine, Baltimore. 443-927-8723
   • MedStar Health Research Institute - Good Samaritan Hospital, Baltimore. 443-444-2263
   • MedStar Union Memorial Hospital, Baltimore. 410-554-4451

2. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

   Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

   2 sites in Maryland

   • Klein & Associates, M.D., P.A., Cumberland. 301-724-4337
   • Klein & Associates, M.D., P.A., Hagerstown. 301-791-6680

3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

   Who can join. Adults 18+, have psoriasis, BMI 27+.

   1 site in Maryland

   • Dermatology and Skin Cancer Specialists, LLC, Rockville

4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   2 sites in Maryland

   • Mercy Medical Center - Baltimore, Baltimore. 410-332-9356
   • Capital Digestive Care - Chevy Chase, Chevy Chase. 301-841-6869

5. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

   Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

   2 sites in Maryland

   • Flourish Research - Bowie, Bowie. 410-824-1341
   • Capitol Cardiology Associates - Lanham Office, Lanham. 561-906-0904

6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   1 site in Maryland

   • Mercy Medical Center, Baltimore. 833-602-2368

7. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 6 to 17, have obesity.

   1 site in Maryland

   • Johns Hopkins Children's Center, Baltimore

8. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

   Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

   1 site in Maryland

   • Capital Digestive Care - Chevy Chase, Chevy Chase

9. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

   Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

   1 site in Maryland

   • Capital Digestive Care - Chevy Chase, Chevy Chase

10. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Maryland

    • Barry J. Reiner, MD LLC, Baltimore

11. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Maryland

    • Endo and Metabolic Consultants, Rockville

12. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Maryland

    • Research Site, Rockville

13. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Maryland

    • Endocrine and Metabolic Consultants, Rockville. 833-602-2368

14. Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Phase 2. Run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Registry number NCT03884075.

    A study testing whether a GLP-1 medicine, semaglutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in Maryland

    • National Institutes of Health Clinical Center, Bethesda. 800-411-1222

15. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Run by Milton S. Hershey Medical Center. Registry number NCT06548490.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in Maryland

    • University of Maryland Baltimore, Baltimore

16. Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

    Phase 2. Run by University of Maryland, Baltimore. Registry number NCT06691243.

    A study of a GLP-1 medicine, semaglutide, in people with cocaine use disorder.

    Who can join. Adults 18 to 65, have cocaine use disorder, BMI 20+.

    1 site in Maryland

    • Institute of Human Virology at the University of Maryland School of Medicine, Baltimore. 443-635-4943

17. Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

    Phase 2. Run by Johns Hopkins University. Registry number NCT06847399.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with binge eating disorder lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    1 site in Maryland

    • Johns Hopkins University, Baltimore. 667-306-9366

18. Tirzepatide in MetALD

    Phase 2. Run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). Registry number NCT07046819.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 21+, have metabolic alcohol-associated liver disease, BMI 25+.

    1 site in Maryland

    • National Institutes of Health Clinical Center, Bethesda. 800-411-1222

19. PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm

    Phase 2. Run by Veru Inc. Registry number NCT07446998.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.

    Who can join. Adults 65+, have obesity or are overweight, BMI 35+.

    1 site in Maryland

    • Centennial Medical Group (CMG), Columbia. 443-698-8678

20. Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Phase 2. Run by Johns Hopkins University. Registry number NCT07497399.

    A study of an investigational medicine, NLY01, in people with multiple sclerosis.

    Who can join. Adults 18 to 60, have multiple sclerosis, BMI 27+.

    1 site in Maryland

    • Johns Hopkins University, Baltimore. 667-306-8153

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact